Brain scans reveal how a calming drug affects emotion in psychosis

NCT ID NCT04004416

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates how a medication called lorazepam, which boosts the calming brain chemical GABA, changes emotional brain activity in people with psychosis. Participants aged 16–60 with conditions like schizophrenia or bipolar disorder, along with healthy volunteers, will undergo brain scans after taking either lorazepam or a placebo. The goal is to better understand the role of GABA in emotional processing and mental illness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lorazepam
What this could lead to
If successful, this could reveal how brain chemistry differs in psychosis, pointing toward better-targeted treatments for emotional symptoms.
What could go wrong
This is an early-phase observational study, not a treatment trial. Lorazepam is used only as a probe, and results may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.